<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00548704</url>
  </required_header>
  <id_info>
    <org_study_id>TT02</org_study_id>
    <nct_id>NCT00548704</nct_id>
  </id_info>
  <brief_title>A Clinical Trial on Topotect® (Dexrazoxane) in the Treatment of Accidental Extravasation of Anthracyclines</brief_title>
  <official_title>A Clinical Trial on Topotect® (Dexrazoxane) in the Treatment of Accidental Extravasation of Anthracycline Anti-cancer Agents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Onxeo</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Onxeo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is

        -  To prevent progression of a lesion caused by anthracycline extravasation into necrosis,
           which would require surgical intervention

        -  To prevent development of deep tissue necrosis and destruction leading to impaired limb
           function and neurological deficit

        -  To prevent postponement of the scheduled cancer treatment due to the treatment of the
           extravasation
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Accidental extravasation of anthracyclines, e.g. doxorubicin and its derivative epirubicin,
      may cause progressive tissue destruction including serious damage of the skin, the
      subcutaneous tissue, muscles, and nerves.

      The patient may suffer from acute local symptoms such as pain and swelling, which may
      progress into blistering and necrosis. Subsequently dysesthesia, skin atrophy, disfigurement,
      and impaired limb function may be the consequence.

      Surgical removal of all affected tissue is required and the debridement often necessitates
      split skin grafting. The patient is thus subjected to the distress of major surgery, which in
      turn leads to delay of further cytotoxic treatment.

      Preclinical animal studies as well as a clinical multicenter phase II trial have demonstrated
      a highly significant efficacy of dexrazoxane in preventing tissue destruction caused by
      anthracyclines.

      This confirmatory trial will determine the effect of Topotect® (dexrazoxane) as an acute
      antidote in patients with anthracycline extravasation.

      Orphan drug status TopoTarget A/S was granted designation for Topotect® as an orphan medical
      product for the treatment of anthracycline extravasations by the European Commission in
      September 2001 and by the FDA in ???.

      Purpose

      Primary objectives:

      • To prevent progression of the anthracycline extravasation lesion as tissue ulceration and
      necrosis requiring surgical intervention

      Secondary objectives:

        -  To prevent development of deep tissue necrosis and destruction leading to late sequelae
           as impaired limb function and neurological deficit

        -  To prevent postponement of the scheduled cancer treatment due to the treatment of the
           extravasation

        -  To evaluate the tolerance to and/or toxicity of Topotect® used for this indication,
           according to the indicated schedule

      Trial design This is an open-label, non-randomised phase II/III trial. Thirty -five evaluable
      patients with anthracycline extravasations will be treated.

      Extravasation is determined by the presence of pain, and/or swelling, and/or redness at the
      site where anthracycline leakage is suspected to have occurred. The extravasations are
      subsequently confirmed in each patient by fluorescence microscopy of at least two punch
      biopsies at the time of the accident.

      Success criteria The prevention of surgical intervention, necrosis and late sequelae
      evaluated 3 months after the extravasation.

      Safety features

        -  Toxicity caused by Topotect® will be examined by haematology and blood chemistry,
           questions are asked on any discomfort. Scheduled clinical examinations are performed

        -  A systematic clinical evaluation of the marked area of skin covering the area of
           extravasation will be performed in order to evaluate the need for surgery

        -  Sequential colour photographs of the involved skin will be taken

      Medical Treatment Patients are treated with intravenous infusion of Topotect® administered
      once daily on three consecutive days at the following doses: 1,000 mg/m2 + 1,000 mg/m2 + 500
      mg/m2. The first dose is administered as soon as possible and within 6 hours of the
      extravasation and the next two doses at 24 and 48 hours after the first infusion.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2002</start_date>
  <completion_date type="Actual">August 2005</completion_date>
  <primary_completion_date type="Actual">August 2005</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">57</enrollment>
  <condition>Extravasation</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexrazoxane</intervention_name>
    <other_name>Totect</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. All cancer patients treated with anthracyclines

          2. Informed consent must be obtained from the patient

          3. Patients suspected to have been exposed to extravasation (leakage) of anthracycline,
             defined as:

               1. A primary assessment by the physician on duty, which would activate the standard
                  departmental procedure for treatment of anthracycline extravasation.

               2. The presence of at least one of the following symptoms: pain, swelling or redness
                  at the site where the anthracycline leakage is suspected to have occurred.

          4. Suspicion of anthracycline extravasation from a central venous access device

          5. The Topotect® infusion must be started &lt; 6 hours after the accident

          6. 18 years of age or older

          7. Performance status (PS) &lt; 2

        Exclusion Criteria:

          1. Known allergy towards dexrazoxane

          2. Reasonable suspicion of extravasation by other compounds than anthracyclines through
             the same intravenous access, e.g. vincristine, mitomycin, and vinorelbine, all of
             which may cause ulceration

          3. AST (aspartate aminotransferase) or ALT (alanine aminotransferase), bilirubin, LDH
             (lactate dehydrogenase), alkaline phosphatase &gt;3 x upper normal value

          4. Neutrophils CTC (common toxicity criteria) ≥ grade 2. (neutrophils 1.5 x 109/L,
             ≥1,500/mm3)

          5. Platelets CTC ≥ grade 2. (platelets ≥75.0 x 109/L, &lt;75,000/mm3).

          6. Topical use of DMSO (dimethylsulfoxide) at the area of the accident

          7. Administration of dexrazoxane within the last 3 weeks

          8. Pregnant or nursing women

          9. Women of childbearing age and potential, who do not use an efficient contraceptive
             (e.g. the Pill or a diaphragm plus a spermicide) for at least 3 months prior to the
             start of trial medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henning T Mouridsen, MD, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, The Finsen Centre 5074, Blegdamsvej 9, DK-2100 Copenhagen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aalborg Hospital South</name>
      <address>
        <city>Aalborg</city>
        <zip>9100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aarhus County Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000 C</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aarhus Municipality Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000 C</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet, Haematology Department</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet, Oncology Department</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Esbjerg District Hospital</name>
      <address>
        <city>Esbjerg</city>
        <zip>6700</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herlev County Hospital, Haematology Department</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herlev County Hospital, Oncology Department</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hilleroed Hospital</name>
      <address>
        <city>Hilleroed</city>
        <zip>3400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Naestved District Hospital</name>
      <address>
        <city>Naestved</city>
        <zip>4700</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000 C</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roskilde County Hospital</name>
      <address>
        <city>Roskilde</city>
        <zip>4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soenderborg Hospital</name>
      <address>
        <city>Soenderborg</city>
        <zip>6400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vejle Hospital</name>
      <address>
        <city>Vejle</city>
        <zip>7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Viborg Hospital</name>
      <address>
        <city>Viborg</city>
        <zip>8800</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evangelisches Bethesda Krankenhaus</name>
      <address>
        <city>Essen Borbak Statt</city>
        <zip>45355</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Gynäkologie und Geburtshilfe</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik für Innere Medizin</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30659</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitäts Frauenklinik</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitäts Medizinische Klinik</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frauenklinik com Roten Kreuz</name>
      <address>
        <city>Munich</city>
        <zip>80637</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitäts Frauenklinik</name>
      <address>
        <city>Rostock</city>
        <zip>18057</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Gynäkologie und Gynäkologische Onkologie</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65199</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale G.B. Morgagni L. Pierantoni</name>
      <address>
        <city>Forli</city>
        <zip>47100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presidio Ospedaliero di Ravenna</name>
      <address>
        <city>Ravenna</city>
        <zip>48100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale degli Infermi</name>
      <address>
        <city>Rimini</city>
        <zip>47037</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti</name>
      <address>
        <city>Trieste</city>
        <zip>34100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Netherland Cancer Institute</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Groningen</city>
        <zip>9700 RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Willem Alexander Hospital</name>
      <address>
        <city>Hertogenbosch</city>
        <zip>5223 GV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre of Oncology - Krakow Division</name>
      <address>
        <city>Krakow</city>
        <zip>31-115</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maria Sklodowska-Curie Memorial Cancer Center</name>
      <address>
        <city>Warsaw</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dolnoslaski Centrum Onkologii oddzial Chemoterapii</name>
      <address>
        <city>Wroclaw</city>
        <zip>53-413</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
  </location_countries>
  <results_reference>
    <citation>Mouridsen HT, Langer SW, Buter J, Eidtmann H, Rosti G, de Wit M, Knoblauch P, Rasmussen A, Dahlstrøm K, Jensen PB, Giaccone G. Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies. Ann Oncol. 2007 Mar;18(3):546-50. Epub 2006 Dec 21.</citation>
    <PMID>17185744</PMID>
  </results_reference>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 23, 2007</study_first_submitted>
  <study_first_submitted_qc>October 23, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2007</study_first_posted>
  <last_update_submitted>October 20, 2015</last_update_submitted>
  <last_update_submitted_qc>October 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Extravasation</keyword>
  <keyword>Anthracyclines</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexrazoxane</mesh_term>
    <mesh_term>Razoxane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

